Cory Kasimov
Stock Analyst at Evercore ISI Group
(4.41)
# 256
Out of 4,827 analysts
81
Total ratings
54.39%
Success rate
18.24%
Average return
Main Sectors:
Stocks Rated by Cory Kasimov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRNA Moderna | Maintains: In-Line | $50 → $32 | $24.38 | +31.26% | 6 | May 2, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Outperform | $190 → $185 | $117.52 | +57.42% | 2 | Apr 24, 2025 | |
| SMMT Summit Therapeutics | Initiates: Outperform | $30 | $24.65 | +21.70% | 1 | Mar 12, 2025 | |
| SWTX SpringWorks Therapeutics | Maintains: Outperform | $60 → $65 | $46.20 | +40.69% | 2 | Feb 12, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $45 → $50 | $34.85 | +43.47% | 3 | Dec 23, 2024 | |
| EWTX Edgewise Therapeutics | Maintains: Outperform | $45 → $50 | $14.70 | +240.14% | 2 | Dec 17, 2024 | |
| BNTX BioNTech SE | Upgrades: Outperform | $110 → $125 | $94.78 | +31.88% | 4 | Nov 19, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Outperform | $115 → $105 | $59.82 | +75.53% | 12 | Oct 30, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $1,250 → $1,175 | $547.67 | +114.55% | 5 | Oct 24, 2024 | |
| ACLX Arcellx | Initiates: Outperform | $85 | $56.26 | +51.08% | 1 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $84 → $88 | $35.96 | +144.72% | 6 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $324 → $276 | $118.39 | +133.13% | 4 | Dec 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $35 | $1.81 | +1,833.70% | 1 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,520 → $780 | $3.71 | +20,924.26% | 5 | Feb 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $225 → $232 | $272.05 | -14.72% | 5 | Jul 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $59.73 | - | 5 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $98.16 | - | 5 | May 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $21 | $30.38 | -30.88% | 4 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $83 → $23 | $3.07 | +649.19% | 6 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $310 → $250 | $9.69 | +2,479.98% | 1 | Feb 14, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $15 → $10 | $0.69 | +1,351.17% | 1 | Feb 14, 2018 |
Moderna
May 2, 2025
Maintains: In-Line
Price Target: $50 → $32
Current: $24.38
Upside: +31.26%
Neurocrine Biosciences
Apr 24, 2025
Maintains: Outperform
Price Target: $190 → $185
Current: $117.52
Upside: +57.42%
Summit Therapeutics
Mar 12, 2025
Initiates: Outperform
Price Target: $30
Current: $24.65
Upside: +21.70%
SpringWorks Therapeutics
Feb 12, 2025
Maintains: Outperform
Price Target: $60 → $65
Current: $46.20
Upside: +40.69%
BridgeBio Pharma
Dec 23, 2024
Maintains: Outperform
Price Target: $45 → $50
Current: $34.85
Upside: +43.47%
Edgewise Therapeutics
Dec 17, 2024
Maintains: Outperform
Price Target: $45 → $50
Current: $14.70
Upside: +240.14%
BioNTech SE
Nov 19, 2024
Upgrades: Outperform
Price Target: $110 → $125
Current: $94.78
Upside: +31.88%
BioMarin Pharmaceutical
Oct 30, 2024
Maintains: Outperform
Price Target: $115 → $105
Current: $59.82
Upside: +75.53%
Regeneron Pharmaceuticals
Oct 24, 2024
Maintains: Outperform
Price Target: $1,250 → $1,175
Current: $547.67
Upside: +114.55%
Arcellx
May 14, 2024
Initiates: Outperform
Price Target: $85
Current: $56.26
Upside: +51.08%
Feb 27, 2024
Maintains: Overweight
Price Target: $84 → $88
Current: $35.96
Upside: +144.72%
Dec 21, 2021
Maintains: Neutral
Price Target: $324 → $276
Current: $118.39
Upside: +133.13%
Mar 1, 2021
Initiates: Neutral
Price Target: $35
Current: $1.81
Upside: +1,833.70%
Feb 17, 2021
Downgrades: Neutral
Price Target: $1,520 → $780
Current: $3.71
Upside: +20,924.26%
Jul 29, 2020
Maintains: Neutral
Price Target: $225 → $232
Current: $272.05
Upside: -14.72%
May 6, 2020
Downgrades: Neutral
Price Target: n/a
Current: $59.73
Upside: -
May 1, 2020
Downgrades: Neutral
Price Target: n/a
Current: $98.16
Upside: -
Feb 14, 2020
Downgrades: Neutral
Price Target: $25 → $21
Current: $30.38
Upside: -30.88%
Nov 2, 2018
Maintains: Underweight
Price Target: $83 → $23
Current: $3.07
Upside: +649.19%
Feb 14, 2018
Maintains: Neutral
Price Target: $310 → $250
Current: $9.69
Upside: +2,479.98%
Feb 14, 2018
Maintains: Underweight
Price Target: $15 → $10
Current: $0.69
Upside: +1,351.17%